• Alien Nathan Edward@lemm.ee
      link
      fedilink
      arrow-up
      53
      ·
      1 year ago

      The secondary patent particularly irked some advocates because the drug’s development was largely underwritten by public funds, according to a 2020 analysis. That study found public sector funds contributed $455 million to $747 million to getting bedaquiline to market, compared to $90 million to $240 million from J&J.

      We pay for the development of the drug, they get the patent, then we pay for the drug. Socialize cost, privatize profits.